Myriad Genetics | Myriad myPath and Myriad RBM

Sell-side

Exclusive Financial Advisor, April 2021

Myriad Genetics | Myriad myPath and Myriad RBM
Myriad myPath acquired by Castle Biosciences (NASDAQ: CSTL) Myriad Rules Based Medicine acquired by Q2 Solutions

Myriad Genetics, Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. Myriad myPath Melanoma, LLC, Laboratory, is Myriad Genetics' laboratory that offers the myPath Melanoma test and has been used by almost 40,000 patients to guide treatment decisions and has been ordered by approximately 20% of dermatopathologists in the country.

More Like This

Jul 2023

Sold Majority Stake in hg medical to Astorg Mid-Cap

Exclusive Financial Advisor

View Details >
May 2023
Jounce Therapeutics Logo

Acquired by Concentra Biosciences

Exclusive Financial Advisor

View Details >
Mar 2023

Smile Source, a Portfolio Company of Brazos Private Equity Partners, has Partnered with Incline Equity Partners

Exclusive Financial Advisor

View Details >